Courtagen taps AWS to deal with the terabytes of information produced in analyzing individuals’ genes to pinpoint disease-causing abnormalities and best treatments.

Brendan McKernan has atrial fibrillation, a condition that causes arrhythmia within the heart. He remembers being asked by his doctor which of 12 drugs that they had tried he liked the fitting.

“I told him I felt terrible on they all,” he recalled, wondering why the doctor hadn’t been ready to prescribe a drug that was right for him. In terms of finding just the best drug, often the sole tool inside the doctor’s medicine bag is trial and mistake.

One drug eventually proved greater than others, but McKernan, president of Courtagen Life Sciences, still wanted a device which could advise a physician regarding which treatment is healthier for the patient, out of several candidates with varying degrees of unwanted effects.

For a spectrum of great ailments referred to as mitochondrial diseases, the firm he co-founded is putting the sort of tool within the hands of doctors. Mitochondrial diseases are believed to result frequently from a genetic mutation. While some things are known about such mutations, it is only recently that particular genomic analysis have been available at what many deem an affordable cost. Using genetic analysis in individual cases holds the promise of more precisely identifying both the mitochondrial disorder that may be afflicting a patient and a likely treatment for it.

[Would like to learn more about genetic analysis engines? See Big Data Startup Eyes Genome Analysis In 4 Hours.]

Mitochondrial diseases include Lou Gehrig’s disease, Huntington’s disease, cerebral palsy, Parkinson’s disease, muscular dystrophy, possibly epilepsy, and doubtless Alzheimer’s. All of them have quite a few potential treatments, and portion of the doctor’s task is matching up the only that’s best for a person patient.

There are few things more individual than DNA. Courtagen is certainly one of progressively more independent labs that, for only $1,000, will analyze a DNA sample that a consumer gives them.

Courtagen runs the tests in its labs. It’s currently averaging 200 new customers a month, each yielding a terabyte of DNA data. The knowledge are shipped to the Amazon Web Services cloud, where they’re referenced by the Courtagen Ziphyr bioinformatics pipeline, an aggregation and analysis engine. Courtagen doesn’t have an IT staff. It has a department of bioinformatics. It developed Ziphyr and runs it on Amazon’s EC2 to research and learn from incoming sequencing information.

With 1 TB of sequencing data in hand for one or several patients, Ziphyr identifies, as precisely as possible, the position and nature of the genetic irregularity or mutation that can be related to a patient’s disease. It then compares that exact data to that of comparable patients.

Ziphyr has access to a database of 14,000 genetic hotspots or “coding non-synonymous variants,” as McKernan put it. A lot is legendary about some human genome variants, little about others.

Ziphyr works with the structured information flow of extra individual genetic information, and likewise an unstructured flow, by which it searches the net for info on cases, published research, and known treatments. “a number of variants aren’t known” within the mitochondrial set of diseases, and different variants carry different levels of pathogenicity, McKernan said.

After analyzing each client’s DNA and examining what’s known about its variants, Ziphyr draws up a report for the patient’s doctor that provides “a powerful list of (mutation) suspects” which are causing the patient’s condition, what’s known in regards to the identified mutations, what treatments exist (and which can be most promising for the person patient), outcomes in related cases, and what similar patients report on their treatments.

Such a report contains significantly better information than before DNA sequencing and Ziphyr analytics, claimed McKernan. A number of his colleagues believe they’re within the advanced laboratory business. McKernan believes he’s within the digital medical information business. “We’re on the forefront of what may be done. We’re seeking the delicate inferences within the [patient’s] data set which are missing in today’s medical systems,” he said.

Courtagen is a 3-year-old company with strong analytics tools in a rapidly emerging field. It desires to maintain its lead and go global fast. It plans to take action although it has yet to construct a datacenter or establish something that appears like a conventional IT department. It uses NetSuite online business applications, while its bioinformatics staff develops the ways that Courtagen uses genetic information in the course of the Ziphyr platform.

The more clients whose genetic code it analyzes, the more valuable its database of decoded information becomes.

Instead of creating datacenters for labs, “we believe we have to specialise in our core competencies,” said McKernan. “Although we needed to be number 1 at running a datacenter, we are not going to compete with Amazon,” he noted.

“As our business expands, we’re going to open labs around the globe. We would have liked a partner with a worldwide presence,” and one which may provide infrastructure that was HIPAA compliant.

Courtagen has developed its own algorithms to make your mind up when to run its analytics jobs inside Amazon. It also uses off-peak spot pricing to get the simplest return on its computing costs. It delivers encrypted genetic data to its clusters within the Amazon Virtual Private Cloud over a personal line, not the web. By way of clusters within the Amazon Virtual Private Cloud, it’s keeping its data-handling HIPAA-complaint.

By building its business out on Amazon, Courtagen believes the corporate can build a huge bioinformatics pipeline. Information will stream in from further and further clients and data sources on the net, and Ziphyr will send out better reports to doctors. If Courtagen can build its practice fast enough, it could become the premier adviser on which drug to apply inside the first place, in preference to on which 12 might work.

Emerging software tools now make analytics feasible — and price-effective — for many companies. Also within the Brave The large Data Wave issue of InformationWeek: Have doubts about NoSQL consistency? Meet Kyle Kingsbury’s Call Me Maybe project. (Free registration required.)

More Insights